Feb 13, 2023
Featuring a slide presentation and related discussion from Dr Edward Garon, including the following topics:
• Immune checkpoint inhibitor therapy for treatment-naïve advanced non-small cell lung cancer (NSCLC) without an actionable mutation (0:00)
• Duration of immunotherapy in the frontline setting for NSCLC with no targetable mutation (13:43)
• New treatment strategies for relapsed or refractory NSCLC with no targetable mutation (16:25)
• Management of antibody-drug conjugate-associated toxicity (19:08)
• Activity of antibody-drug conjugates alone or in combination with anti-PD-1 antibodies (26:18)